Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
medical ozone gas
- Development stage
- Unknown
- Lead developer
- Centro Ginecológico Ginfer
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
Medical ozone gas is an investigational therapeutic agent consisting of ozone (O3), a triatomic molecule of oxygen. It is being evaluated by Centro Ginecológico Ginfer for applications in reproductive medicine, specifically for women with recurrent implantation failure (RIF) and recurrent pregnancy loss. The treatment involves intrauterine instillation of the gas, which is hypothesized to modulate the uterine environment by influencing uterine natural killer (uNK) cells and improving embryo implantation rates. Currently, it is being studied in a Phase 3 clinical trial in Spain for patients undergoing deferred embryo transfer.
- Other names
- ozoneO3O-3O 3medical ozone
Beyond the preview
Go deeper on medical ozone gas.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on medical ozone gas.